{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T21:12:16Z","timestamp":1772053936784,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02992"],"award-info":[{"award-number":["21H02992"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtn.2023.102079","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T11:35:58Z","timestamp":1700048158000},"page":"102079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antitumor effects of chemically modified miR-143 lipoplexes in a mouse model of pelvic colorectal cancer via myristoylated alanine-rich C kinase substrate downregulation"],"prefix":"10.1016","volume":"34","author":[{"given":"Jun","family":"Arima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-1370","authenticated-orcid":false,"given":"Kohei","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Sugito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Heishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Tokumaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masa-Aki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.102079_bib1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.omtn.2023.102079_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.omtm.2019.02.005","article-title":"Anti-cancer effects of a chemically modified miR-143 on bladder cancer by either systemic or intravesical treatment","volume":"13","author":"Yoshikawa","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2023.102079_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/cas.14694","article-title":"PTBP1-targeting microRNAs regulate cancer-specific energy metabolism through the modulation of PKM1\/M2 splicing","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omtn.2023.102079_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00063030-200923010-00002","article-title":"MicroRNA-based therapeutics for cancer","volume":"23","author":"Wang","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtn.2023.102079_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gendis.2014.06.004","article-title":"MicroRNAs in cancer biology and therapy: current status and perspectives","volume":"1","author":"Price","year":"2014","journal-title":"Genes Dis."},{"key":"10.1016\/j.omtn.2023.102079_bib6","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1021\/acs.molpharmaceut.9b00680","article-title":"\u03b1-Aminoisobutyric acid-containing amphipathic helical peptide-cyclic RGD conjugation as a potential drug delivery system for microRNA replacement therapy in\u00a0vitro","volume":"16","author":"Taniguchi","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2023.102079_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1254\/jphs.10R12FM","article-title":"MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug","volume":"114","author":"Kitade","year":"2010","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2023.102079_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.omtn.2022.09.001","article-title":"Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells","volume":"30","author":"Sugito","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.102079_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/cgt.2009.88","article-title":"Role of anti-oncomirs miR-143 and -145 in human colorectal tumors","volume":"17","author":"Akao","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtn.2023.102079_bib10","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.102079_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ymthe.2019.03.004","article-title":"Synthetic miR-143 exhibited an anti-cancer effect via the downregulation of K-RAS networks of renal cell cancer cells in\u00a0vitro and in\u00a0vivo","volume":"27","author":"Takai","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2023.102079_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejpb.2018.04.018","article-title":"Non-viral based miR delivery and recent developments","volume":"128","author":"Labatut","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.omtn.2023.102079_bib13","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2023.102079_bib14","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1093\/nar\/gkv762","article-title":"Identification of siRNA delivery enhancers by a chemical library screen","volume":"43","author":"Gilleron","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2023.102079_bib15","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.omtn.2023.102079_bib16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(86)91510-2","article-title":"Recurrence and survival after total mesorectal excision for rectal cancer","volume":"1","author":"Heald","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2023.102079_bib17","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.ejca.2008.05.004","article-title":"Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and pre-operative radiotherapy","volume":"44","author":"den Dulk","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omtn.2023.102079_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/SLA.0000000000002212","article-title":"Mesorectal excision with or without lateral lymph node dissection for clinical stage II\/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial","volume":"266","author":"Fujita","year":"2017","journal-title":"Ann. Surg."},{"key":"10.1016\/j.omtn.2023.102079_bib19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00000658-199410000-00017","article-title":"Pelvic resection of recurrent rectal cancer","volume":"220","author":"Wanebo","year":"1994","journal-title":"Ann. Surg."},{"key":"10.1016\/j.omtn.2023.102079_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56152-0","article-title":"An in\u00a0vivo mouse model of pelvic recurrence of human colorectal cancer","volume":"9","author":"Yamamoto","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2023.102079_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113632","article-title":"Anti-tumor effect of boron neutron capture therapy in pelvic human colorectal cancer in a mouse model","volume":"154","author":"Arima","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtn.2023.102079_bib22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10555-017-9709-6","article-title":"Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers","volume":"36","author":"Fong","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.omtn.2023.102079_bib23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2015.11.002","article-title":"Liver bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis","volume":"64","author":"Eguchi","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.omtn.2023.102079_bib24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/gutjnl-2019-318817","article-title":"MiR130b from Schlafen4(+) MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer","volume":"69","author":"Ding","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.omtn.2023.102079_bib25","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3390\/cancers14122969","article-title":"Validation of a patient-derived xenograft model for cervical cancer based on genomic and phenotypic characterization","volume":"14","author":"Miyamoto","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omtn.2023.102079_bib26","first-page":"484","article-title":"Orthotopic mouse model of colorectal cancer","volume":"10","author":"Tseng","year":"2007","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.omtn.2023.102079_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000085342","article-title":"Mouse models of colorectal cancer and liver metastases","volume":"22","author":"Heijstek","year":"2005","journal-title":"Dig. Surg."},{"key":"10.1016\/j.omtn.2023.102079_bib28","first-page":"16","article-title":"Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans","volume":"50","author":"Kobaek-Larsen","year":"2000","journal-title":"Comp. Med."},{"key":"10.1016\/j.omtn.2023.102079_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.2910520118","article-title":"Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil","volume":"52","author":"Wilmanns","year":"1992","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtn.2023.102079_bib30","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3390\/ijms20071697","article-title":"Synthetic miR-143 inhibits growth of HER2-positive gastric cancer cells by suppressing KRAS networks including DDX6 RNA helicase","volume":"20","author":"Tokumaru","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2023.102079_bib31","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/cas.13559","article-title":"Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143","volume":"109","author":"Akao","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omtn.2023.102079_bib32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0021-9258(18)53878-3","article-title":"The MARCKS family of cellular protein kinase C substrates","volume":"268","author":"Blackshear","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2023.102079_bib33","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.7150\/thno.53558","article-title":"MARCKS cooperates with NKAP to activate NF-\u03baB signaling in smoke-related lung cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2023.102079_bib34","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1038\/s41388-020-01511-9","article-title":"A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma","volume":"39","author":"Eustace","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2023.102079_bib35","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3892\/mmr.2017.6108","article-title":"miR-34c-3p acts as a tumor suppressor gene in osteosarcoma by targeting MARCKS","volume":"15","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.omtn.2023.102079_bib36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2009.03.077","article-title":"MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells","volume":"383","author":"Li","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2023.102079_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12929-018-0445-1","article-title":"MARCKS and MARCKS-like proteins in development and regeneration","volume":"25","author":"El Amri","year":"2018","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.omtn.2023.102079_bib38","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1164\/rccm.201408-1505OC","article-title":"Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. mechanisms and therapeutic implications","volume":"190","author":"Chen","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.omtn.2023.102079_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.omtn.2023.102079_bib40","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/ijms19051276","article-title":"Organ-specific microRNAs (MIR122, 137, and 206) contribute to tissue characteristics and carcinogenesis by regulating pyruvate kinase M1\/2 (PKM) expression","volume":"19","author":"Taniguchi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2023.102079_bib41","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.3390\/ijms23095230","article-title":"Downregulation of miR-122-5p activates glycolysis via PKM2 in Kupffer cells of rat and mouse models of non-alcoholic steatohepatitis","volume":"23","author":"Inomata","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123002974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:21:37Z","timestamp":1762600897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123002974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":41,"alternative-id":["S2162253123002974"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102079","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor effects of chemically modified miR-143 lipoplexes in a mouse model of pelvic colorectal cancer via myristoylated alanine-rich C kinase substrate downregulation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.102079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"102079"}}